Urogen Pharma Ltd (NASDAQ:URGN) has been given an average recommendation of “Buy” by the ten research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $63.67.

A number of analysts have recently weighed in on URGN shares. Oppenheimer set a $75.00 price objective on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Tuesday, May 22nd. Cowen restated a “buy” rating on shares of Urogen Pharma in a research note on Tuesday, August 14th. ValuEngine upgraded shares of Urogen Pharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Finally, Stifel Nicolaus began coverage on shares of Urogen Pharma in a research note on Thursday. They issued a “buy” rating for the company.

Shares of Urogen Pharma stock traded up $1.19 on Tuesday, reaching $45.76. The stock had a trading volume of 4,694 shares, compared to its average volume of 64,120. Urogen Pharma has a fifty-two week low of $25.56 and a fifty-two week high of $69.57. The stock has a market capitalization of $603.69 million, a price-to-earnings ratio of -21.38 and a beta of 1.98.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.25). Urogen Pharma had a negative return on equity of 44.24% and a negative net margin of 470.54%. The firm had revenue of $0.36 million during the quarter. equities research analysts anticipate that Urogen Pharma will post -4.16 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in Urogen Pharma during the 2nd quarter valued at $227,000. California Public Employees Retirement System acquired a new position in Urogen Pharma during the 2nd quarter valued at $840,000. Millennium Management LLC raised its stake in Urogen Pharma by 8.3% during the 2nd quarter. Millennium Management LLC now owns 172,332 shares of the company’s stock valued at $8,575,000 after purchasing an additional 13,219 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Urogen Pharma during the 2nd quarter valued at $333,000. Finally, Wildcat Capital Management LLC raised its stake in Urogen Pharma by 38.4% during the 2nd quarter. Wildcat Capital Management LLC now owns 251,459 shares of the company’s stock valued at $12,513,000 after purchasing an additional 69,757 shares during the last quarter. Hedge funds and other institutional investors own 71.11% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

See Also: Book Value Of Equity Per Share – BVPS Explained

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.